following a full submission
alemtuzumab (Lemtrada®) is accepted for use within NHS Scotland.
Indication under review: For adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
Two phase III studies comparing alemtuzumab with interferon beta-1a in treatment-naive (CARE-MS I) and treatment-experienced (CARE-MS II) patients with relapsing remitting multiple sclerosis both showed a statistically significant relative decrease in relapse rate of 55% and 49% respectively in favour of alemtuzumab. There was a significant reduction in the risk of sustained accumulation of disability over 6 months of 42% in CARE-MS II, but for CARE-MS-I, this was not statistically significant.
|Drug Name:||alemtuzumab (Lemtrada)|
|SMC Drug ID:||959/14|
|Manufacturer:||Genzyme Therapeutics Ltd|
|Indication:||For adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.|
|Submission Type:||Full submission|
|Date Advice Published:||7 July 2014|